Four Leukemic Stem Cell Subtypes Explain Venetoclax Resistance in AML
Researchers identify four LSC subtypes that predict venetoclax resistance and reveal matched subtype-specific therapies for AML patients.
Summary
Venetoclax, a BCL-2 inhibitor, has revolutionized acute myeloid leukemia treatment, but many patients relapse. A new study profiling leukemic stem cells from over 150 AML patients found four distinct stem cell subtypes that mirror normal blood cell development stages. Each subtype has a different balance of survival proteins — BCL-2, MCL-1, and BCL-xL — captured in a new scoring tool called the MAC-score. The most common resistance mechanism involves stem cells shifting toward a megakaryocytic/erythroid state that depends on BCL-xL instead of BCL-2. A rarer monocytic subtype drives resistance differently. Crucially, each resistant subtype responds to a different targeted therapy, opening the door to personalized, biomarker-guided treatment strategies that go beyond genetic risk alone.
Detailed Summary
Venetoclax has transformed acute myeloid leukemia (AML) treatment, but durable remission remains elusive for many patients. Relapse is frequently driven by leukemic stem cells (LSCs) that survive therapy — and understanding why has been a major unsolved problem in hematology oncology.
This landmark study from German Cancer Research Center and collaborators molecularly and functionally profiled LSCs from more than 150 AML patients, identifying four distinct LSC subtypes that mirror normal hematopoietic lineage stages. The researchers developed a biomarker called the MAC-score, which captures the expression ratio between BCL-2 (venetoclax's target) and resistance-associated proteins MCL-1 and BCL-xL, providing a predictive readout of likely treatment response.
The key mechanistic finding is that venetoclax resistance primarily arises through LSC plasticity — specifically, cells shift toward a megakaryocytic/erythroid progenitor (MEP-LSC) state that switches survival dependence from BCL-2 to BCL-xL. A rarer resistance pathway involves mature monocytic/dendritic LSCs (MoDe-LSCs) found in LAMP5+ monocytic AMLs. These two resistant populations require distinct therapeutic approaches: MEP-LSCs respond to BCL-xL inhibitors, while MoDe-LSCs are sensitive to MEK1/2 inhibition.
Beyond resistance mechanisms, LSC subtyping was shown to improve upon standard genetic risk stratification, suggesting it could refine prognosis and treatment selection in clinical practice. The MAC-score is the subject of a patent application, indicating active steps toward clinical translation.
Caveats include the abstract-only basis for this summary, limiting assessment of statistical rigor and the specific functional assays used. Whether the MAC-score and LSC subtyping will prospectively validate in randomized trials remains to be seen. Nonetheless, this work represents a significant conceptual advance in AML biology and precision oncology.
Key Findings
- Four LSC subtypes in AML mirror hematopoietic lineage stages and predict venetoclax response via MAC-score.
- Most venetoclax resistance arises from LSC plasticity shifting to a MEP state dependent on BCL-xL over BCL-2.
- Rare monocytic MoDe-LSCs in LAMP5+ AMLs drive resistance through a distinct mechanism sensitive to MEK1/2 inhibitors.
- MEP-LSC-driven resistant disease responds to BCL-xL inhibitors, enabling subtype-matched therapy.
- LSC subtyping improves genetic risk stratification and supports biomarker-guided treatment selection.
Methodology
The study performed molecular and functional profiling of leukemic stem cells from more than 150 AML patients, identifying four LSC subtypes. Longitudinal analyses tracked how LSC subtype composition shifted in response to venetoclax treatment. A novel MAC-score was developed to quantify the BCL-2 to MCL-1/BCL-xL expression ratio as a resistance biomarker.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access, limiting evaluation of statistical methodology and validation cohort details. The MAC-score is patent-pending, which may introduce commercialization bias. Prospective clinical validation of LSC subtype-guided therapy is still needed before routine clinical adoption.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.